| Abstract O43 – Table 1. Baseline characteristics. | ||
|---|---|---|
| Baseline characteristics | Total | Observed data |
| Sex, male, % (n) | 95.3% (225) | 236 |
| Age, years, median (IQR) | 43 (36 to 50) | 236 |
| Age categories <50; 50 to 65; >65, % (n) | 74.6% (176); 25.0% (59); 0.4% (1) | 236 |
| BMI ≥30 kg/m2, % (n) | 12.2% (23) | 189 |
| CD4 T‐cell count, cells/μL, median (IQR) | 721 (542 to 991) | 232 |
| History of AIDS (CDC C), % (n) | 8.5% (20) | 236 |
| Time on ART, years (median, IQR) | 8.0 (4.9 to 11.6) | 210 |
| ≥3 previous ART regimens, % (n) | 53.8% (106) | 197 |
| Most common regimens (>10%) prior to switch to CAB+RPV LA | B/F/TAF: 24.0% (n = 55); DTG/3TC: 18.8% (n = 43) | 229 |
| Reason for switch to CAB+RPV LA (HCP perspective) | 236 | |
| Patient wish | 91.9% (n = 217) | |
| Adherence concerns under oral ART | 5.5% (n = 13) | |
| Medical need for parent | 1.7% (n = 4) | |
| Other | 0.8% (n = 2) | |
| Resistance test available at/before switch to CAB+RPV LA | 60.6% (n = 143) | 236 |
| HIV‐1 subtype | 236 | |
| A | 0.8% (n = 2) | |
| A1 | 1.3% (n = 3) | |
| A2 | 2.1% (n = 5) | |
| B | 50.4% (n = 119) | |
| Other | 5.1% (n = 12) | |
| Unknown subtype | 40.3% (n = 95) | |
B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide; DTG/3TC, dolutegravir/lamivudine; IQR, interquartile range.